Skip to content
It's time to build
Nav Opener
  • Portfolio
  • Team
  • Focus Areas
    • Bio
    • Cultural Leadership Fund
    • Consumer
    • Crypto
    • Enterprise
    • Fintech
    • Growth
    • Talent x Opportunity
  • Content
    Topics
    • Fintech
    • Gaming & Social
    • Security & Privacy
    • Marketplaces
    • Enterprise & SaaS
    • Bio
    • Creator Economy
    • Cryptocurrencies & Blockchains
    Type
    • Articles
    • Video
    • Podcasts
    • Newsletters
  • About
Close

Judy Savitskaya

Judy Savitskaya Twitter

Judy is a partner on the bio investing team. She focuses on early stage companies in digital health and bioengineering.

Prior to joining Andressen Horowitz, Judy worked on synthetic biology research with Professors Adam Arkin and John Dueber at UC Berkeley, where she engineered organisms to produce high value pharmaceuticals and developed methods for improving these organisms using high throughput genome sequencing strategies. Before picking up her first pipette, Judy published several research projects in the computational modeling and simulation of neuronal networks.

Judy holds a BS in Computational Biology from the School of Computer Science at Carnegie Mellon. She studied for an MPhil in Plant Sciences from Cambridge University under a Churchill Scholarship. Judy completed her PhD in Bioengineering in the Joint UCSF-UC Berkeley Bioengineering Program, where she was awarded NDSEG and Hertz Fellowships to fund her research. While at Berkeley, Judy was also selected as a Mayfield Entrepreneurial Fellow.

Latest Posts

Journal Club: Assembling an Egg

by Vineeta Agarwala, Justin Larkin, Judy Savitskaya, and Lauren Richardson
  • bio
  • a16z Journal Club
  • genetics
  • genomics

Journal Club: Engineering Living Materials

by Tom Ellis, Judy Savitskaya, and Lauren Richardson
  • bio
  • a16z Journal Club
  • genetics
  • synthetic biology
  • when science becomes engineering

The Second Coming of RNA Medicines

by Judy Savitskaya
  • bio
  • coronavirus & the COVID-19 pandemic
  • drug development
  • therapeutics
  • when science becomes engineering

What is a Bio Platform For?

by Judy Savitskaya and Jorge Conde
  • bio
  • full stack startups
  • go to market
  • Company Building 101
  • healthcare
  • platform shifts
  • therapeutics
  • when science becomes engineering

From @heyjudka

ian đź”®@IanRountree

7 Powers crew, @heyjudka & I think culture might be an 8th power—e.g. PayPal early on, SpaceX/Tesla, maybe even Uber’s early days. It can be a concrete differentiator that isn’t easily copied (à la process power). Thoughts @djrosent @gilbert @packyM @CGarrett_15?

Judy Savitskaya@heyjudka

This hits hard. Modeling in biology is so often just a confirmatory epilogue in a paper rather than used as the powerful tool it can be. https://t.co/z30I8PO4vq

Surge Biswas@SurgeBiswas

We are excited to have our Low-N protein design paper out in Nature Methods today! Absolute delight working with @grigonomics @EthanAlley @kesvelt and @geochurch https://t.co/Ix2umFBFZK

Software is eating the world
© 2021 Andreessen Horowitz
Software is eating the world
    • Twitter
    • Simplecast
  • Contact
  • Jobs
  • Briefings
  • Terms of Use & Privacy
  • Disclosures
  • Conduct
  • Who We Are